The ability of biomarkers to assess the severity of atopic dermatitis
Journal of Allergy and Clinical Immunology: Global · 2024-02 · 3 (1) · 100175
DOI: 10.1016/j.jacig.2023.100175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2024-02. Verfasst von Takeshi Nakahara und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Fondation Sanofi Espoir.
Abstract (Originalsprache)
Background
To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD.
Objective
The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD.
Methods
We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline.
Results
We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses.
Conclusion
We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Oral Microbe Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
- Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan.
Förderung
- Regeneron Pharmaceuticals Inc
- Fondation Sanofi Espoir
Zitieren
APA
Nakahara, T., Onozuka, D., Nunomura, S., Saeki, H., Takenaka, M., Matsumoto, M., Kataoka, Y., Fujimoto, R., Kaneko, S., Morita, E., Tanaka, A., Saito, R., Okano, T., Miyagaki, T., Aoki, N., Nakajima, K., Ichiyama, S., Kido-Nakahara, M., Tonomura, K., …, & Izuhara, K. (2024). The ability of biomarkers to assess the severity of atopic dermatitis. Journal of Allergy and Clinical Immunology: Global, 3(1), 100175. https://doi.org/10.1016/j.jacig.2023.100175
Vancouver
Nakahara T, Onozuka D, Nunomura S, Saeki H, Takenaka M, Matsumoto M, et al. The ability of biomarkers to assess the severity of atopic dermatitis. Journal of Allergy and Clinical Immunology: Global. 2024;3(1):100175. doi:10.1016/j.jacig.2023.100175
BibTeX
@article{Nakahara2024,
author = {Nakahara, Takeshi and Onozuka, Daisuke and Nunomura, Satoshi and Saeki, Hidehisa and Takenaka, Motoi and Matsumoto, Mai and Kataoka, Yoko and Fujimoto, Rai and Kaneko, Sakae and Morita, Eishin and Tanaka, Akio and Saito, Ryo and Okano, Tatsuro and Miyagaki, Tomomitsu and Aoki, Natsuko and Nakajima, Kimiko and Ichiyama, Susumu and Kido-Nakahara, Makiko and Tonomura, Kyoko and Nakagawa, Yukinobu and Tamagawa-Mineoka, Risa and Masuda, Koji and Takeichi, Takuya and Akiyama, Masashi and Ishiuji, Yozo and Katsuta, Michie and Kinoshita, Yuki and Tateishi, Chiharu and Yamamoto, Aya and Morita, Akimichi and Matsuda-Hirose, Haruna and Hatano, Yutaka and Kawasaki, Hiroshi and Fukushima-Nomura, Ayano and Ohtsuki, Mamitaro and Kamiya, Koji and Kabata, Yudai and Abe, Riichiro and Mitsui, Hiroshi and Kawamura, Tatsuyoshi and Tsuji, Gaku and Katoh, Norito and Furue, Masutaka and Izuhara, Kenji},
title = {The ability of biomarkers to assess the severity of atopic dermatitis},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2024},
volume = {3},
number = {1},
pages = {100175},
doi = {10.1016/j.jacig.2023.100175}
}
EUVIMED